- Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
and other study procedures.
- Participated for a minimum of 16 weeks after the initiation of the last course of
treatment in a previous rheumatoid arthritis study in the rituximab-Pfizer program
within the past 2 months.
- Investigational site staff members or relatives of those site staff members or
subjects who are Pfizer employees directly involved in the conduct of the study.
- Initiated treatment with investigational agents or other biologics (including Rituxan
and MabThera) since participating in a previous rheumatoid arthritis study in the
rituximab-Pfizer program.